Evaluation of the consumption of medicines for the treatment of obesity: a study conducted in pharmacy of Teresina-Piauí municipality
DOI:
https://doi.org/10.33448/rsd-v9i3.2293Keywords:
Obesity; Self-Medication; Prevalence; Irrational Use of Medicines.Abstract
Obesity is a disease considered as a global epidemic. In Brazil, obesity been increasing in all age groups without distinction of sex. Together with obesity another concern arises, the indiscriminate and abusive use of medications for the treatment of this patology. The aim of this article was to identify wich drugs for the treatment of obesity are most for the treatment of this pathology consumed in the Teresina city. It was observed that the most commercialized drug for treatment obesity is Sibutramine, followed by Orlistate, Fluoxetine, Duloxitin and Topiramate. Remembering that the last three are off label medications(outside the leaflet) i.e. are marketed for the treatment of anxiety and depression. The highest service was for female users, between 20 to 29 years old. It was observed in the study that some users do not always make the correct use of the medicines, and, the influences of third parties are part of the processes seduced by advertising of the pharmaceutical industries.
References
Associação Brasileira Para o Estudo da Obesidade e Síndrome Metabólica. [acesso 20 nov.2019]. 4ª ed. Dispo- nível em: http://www.abeso.org.br/uploads/ downloads/92/57 fccc403e5da.pdf.
Agne, A. A.; Daubert,). R.; Munoz, M.L; Scarinci, I. Cherrington, A. L.; (2012). The cultural context of obesity: Exploring Perceptions of Obesity and Weight Loss Among Latino immigrants. J Immigr Minor Health. 14(6): 1063-70.
Ali Khan, R.; Kapur, P.; Jain, A.; et al. (2017). Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades off atty liver in obese NAFLD patients. Therapeutic and Clinical Risk Management.13: 139–149.
Arrais, P. S. D.; Fernandes, M. E. P.; Dal Pizzol, T. S.; et al.(2017). Prevalência da Automedicação no Brasil e Fatores Associados. Revista de Saúde Pública. 2. (50).
Brasil2009). [acesso em: 20/11/2019]. O Sistema Nacional de Gerenciamento de Produtos Controlados (SNGPC) Relatório 2009. Disponível em: www.anvisa.gov.br/sngpc/relatório2009.
Bernardi, S.; Pallanti, S.; (2010). Success full duloxetine treatment of a binge eating disorder: a case report. Journal Psychopharmacol 24(8): 1269-1272.
Brasil.(2012). Comissão Nacional de Incorporação de Tecnologias no SUS, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Uso off label: erro ou necessidade?. Rev. Saúde Pública. 46(2): 395-397.
Carlini, E. A.; Noto, A. R.; Nappo, S. A.; (2009).Fluoxetina: indícios de uso inadequado. J.Bras. Psiquiatra 58(2): 97-100.
Conte, S. C.; Campos, S. B.;(2015). Perspectivas de perda de Peso com o Uso da Liraglutida: revisão da literatura. Brazilian Journal of Surgery and Clinical Research – BJSCR. 9(1): 84-90.
Chojnacki, C.; Walecka-Kapica, E.; Klupinska, G.;(2015). Effects of Fluoxetine and Melatonin on Mood, Sleep Quality and Body Mass Index in Post Menopausal Women. Journal of Physiology and Pharmacology. 66(5): 665-671.
Chudasama, H. P.; Bhatt, P. A.; (2009). Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along withits anti-depressant activity: an experimental study in obeserats. Canadian Journal of Physiology and Pharmacology. 87(11), 900-907.
Douglas, I. J.; Bhaskaran, K.; Batterham, R. L.; (.2015). Smeeth. The Effectiveness Of Pharmaceutical Interventions for Obesity: Weightloss With Orlistat and Sibutramine in a United Kingtom Population-Based Cohort. British Journal of Clinical Pharmacology. v. 10, n. 11.
Faria, A. M.; Mancini, M. C.; Melo, M. E.; Cercato, C.; Halpern, A.; (2010). Progressos recentes e novas perspectivas em farmacoterapia da obesidade. Arquivo Brasileiro Endocrinologia Metabolismo. 54(6), 516-529.
Ferreira, L.; Gomes, E.; (2009). Estudo Sobre a Eficácia do Uso de Inibidores da Recaptação de Norepinefrina e Serotonina no Tratamento da obesidade (Sibutramina®). Revista Saúde e Pesquisa. 2, 363-369.
Franco, R. R.; Cominato, L.; Damiani, D.;(2014). O Efeito da Sibutramina na Perda de Peso de Adolescentes Obesos. Arquivo Brasileiro de Endocrinologia e Metabolismo.58(3).
Guisado-Macías, J. A.; Méndez-Sánchez, F.;Baltasar-T, I.; et al.;(2016). Fluoxetine, topiramate, and combination of both to stabilize eating behavior before bariatric surgery. Actas Esp Psiquiatr. .44(3): 93-96.
Heinkel, T. M.; Bilibio, B. L. E.; Ferreira, D. F. Uma Revisão Bibliográfica Sobre o Transtorno da Compulsão Alimentar Periódica (TCAP) Salão do Conhecimento Brasil. 2016; 2(2).
Hochman, B.; Nahas, X.F.; Filho, de O. S.R.; Ferreira, M.L.; (2005). Desenhos de pesquisa. Acta Cirúrgica Brasileira, 20 (2).
Kristensen, M.; Juul, S. R.; Sorensen, K. V.; etal.; (2017). Supplementation with dairy calcium and orflaxseed fibers in conjunction with orlistat augments fecal fatexcretion with out altering ratings of gastrointestinal comfort. Nutrition & Metabolism. 14(13).
Kyung Sun, B.; Hye Kim, J.; Choi, JS.; et al.; (2015). Fluoxetine Decreases the Proliferation and Adipogenic Differentiation of Human Adipose-Derived Stem Cells. International Journal Molecular Sciences.16 (7): 16655-16668
Londoño-Lemos, M.H.(2012).Tratamiento Farmacológico Contra La Obesid. Revista Colômbia Ciência Química Farmacológica. 27(2): 217-261.
Mancini, M. C.; Halpern, A. Pharmacological treatment of Obesity. Arq. Bras. Endocrinol. Metabol. 2002; 40(5): 497-513.
Maqsood, M.; Ahmed, D.; Atique, A.; Malik, W.; (2017). Lipase inhibitory activity of Lagenaria siceraria fruit as a strategy to treat obesity. Asian Pacific Journal of Tropical Medicine. 10(3):305–310.
Marcon, C.; Silva, L. A. M.; Moraes, C. M. B.; Martins, J. S.;et al.; (2012). Uso de Anfetaminas e Substâncias Relacionadas na Sociedade Contemporânea. Revista disciplinarium scientia. Série: ciências da saúde, Santa Maria. 13(2): 247-263.
Martins, M. C. C.; Filho, M. D.; Moura, F. S.;et al.; (2011).. Uso de Drogas Antiobesidade Entre Estudantes Universitários. Revista Associação Médica Brasileira. 57(5): 570-576.
Massoni, T; Suyenaga, E. S.;(2012). Sibutramina Sob a Óptica da Química Medicinal. Revista Eletrônica de Farmácia. 4, 59-68.
Naccarato, C. M.; Lago, O. M. E. (2014). Uso dos Anorexígenos e Anfepramona e Sibutramina: Benefícios ou Prejuízo à Saúde? Revista Saúde. 8 (1/2): 66-72.
Naravarini, M. M.; Deuschle, N. K. C. V.; (2014). Cross- Sectional Study of the Dispensation of Synthetic Anorectic Drugs in Community of Pharmacies in the City of Cruz Alta- State of Rio Grande do Sul, Brazil. Article Brazilian Journal of Pharmaceutical sciences. 50(4).
Neto, D. C.; Souza, A. P. B.; Pilonetto, R. L.;et al.; (2017). O Uso Off Label de Psicotrópicos no Tratamento da Obesidade. Revista Científica Multidisciplinar Núcleo do Conhecimento. 2(16):308-320.
Oliveira, K. R.; Buzanelo, V. V.; (2011). Análise das Prescrições de Medicamentos Usados no Tratamento da Obesidade Dispensadas em Drogarias no Município de Ijuí- RS. Revista de Ciências Farmacêuticas Básica e Aplicada. 32(3):381-387.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.